-
EP4146228
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4146228
| EP4146228 - COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 10.02.2023 Database last updated on 16.11.2024 | |
| Former | The international publication has been made Status updated on 12.11.2021 | Most recent event Tooltip | 27.09.2024 | Supplementary search report | published on 30.10.2024 [2024/44] | 27.09.2024 | Change - classification | published on 30.10.2024 [2024/44] | 27.09.2024 | Change - classification | published on 30.10.2024 [2024/44] | Applicant(s) | For all designated states Shanghai Huayu Biotechnology Co., Ltd. Block D, 7th Floor, Building 8 No 200, Newton Road China (Shanghai) Pilot Free Trade Zone 201203 / CN | [2023/11] | Inventor(s) | 01 /
WU, Zhanggui Brookline, MA 02446 / US | [2023/11] | Representative(s) | Krauss, Jan SKM-IP PartGmbB Oberanger 45 80331 München / DE | [2023/11] | Application number, filing date | 21800036.2 | 03.05.2021 | [2023/11] | WO2021US30402 | Priority number, date | US202063021206P | 07.05.2020 Original published format: US 202063021206 P | [2023/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021225926 | Date: | 11.11.2021 | Language: | EN | [2021/45] | Type: | A1 Application with search report | No.: | EP4146228 | Date: | 15.03.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.11.2021 takes the place of the publication of the European patent application. | [2023/11] | Search report(s) | International search report - published on: | US | 11.11.2021 | (Supplementary) European search report - dispatched on: | EP | 26.09.2024 | Classification | IPC: | A61K31/7076, A61K31/675, A61K31/52, A61K39/00 | [2024/44] | CPC: |
A61K45/06 (EP);
A61K31/52 (US);
A61K31/7076 (EP);
A61P35/02 (EP,US);
C07K16/2818 (EP);
C07K16/2896 (US);
A61K2039/505 (EP)
(-)
| C-Set: |
A61K31/7076, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (EP) |
| Former IPC [2023/11] | A61K31/7076, A61K31/675, A61K31/52 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/11] | Title | German: | KOMBINATIONSKREBSTHERAPIE MIT N2-CHINOLIN- ODER ISOCHINOLIN-SUBSTITUIERTEN PURINDERIVATEN | [2023/11] | English: | COMBINATION CANCER THERAPY USING N2-QUINOLINE OR ISOQUINOLINE SUBSTITUTED PURINE DERIVATIVES | [2023/11] | French: | POLYTHÉRAPIE ANTICANCÉREUSE FAISANT APPEL À DES DÉRIVÉS DE PURINE SUBSTITUÉS PAR N2-QUINOLÉINE OU ISOQUINOLÉINE | [2023/11] | Entry into regional phase | 07.12.2022 | National basic fee paid | 07.12.2022 | Search fee paid | 07.12.2022 | Designation fee(s) paid | 07.12.2022 | Examination fee paid | Examination procedure | 07.12.2022 | Examination requested [2023/11] | 06.06.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 21.03.2023 | Renewal fee patent year 03 | 28.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2005097135 (NOVARTIS AG [CH], et al); | International search | [Y]US2006293274 (WU ZHANGGUI [US]); | [A]US2012149701 (REN PINGDA [US], et al); | [Y]US2016207924 (WU GUOFENG [CN], et al); | [Y]US2017239351 (HAMDY AHMED [US], et al); | [Y]WO2019152743 (CELGENE CORP [US]) |